دورية أكاديمية
Human Triosephosphate Isomerase Is a Potential Target in Cancer Due to Commonly Occurring Post-Translational Modifications.
| العنوان: | Human Triosephosphate Isomerase Is a Potential Target in Cancer Due to Commonly Occurring Post-Translational Modifications. |
|---|---|
| المؤلفون: | Enríquez-Flores S; Laboratorio de Biomoléculas y Salud Infantil, Instituto Nacional de Pediatría, Secretaría de Salud, Mexico City 04530, Mexico., De la Mora-De la Mora I; Laboratorio de Biomoléculas y Salud Infantil, Instituto Nacional de Pediatría, Secretaría de Salud, Mexico City 04530, Mexico., García-Torres I; Laboratorio de Biomoléculas y Salud Infantil, Instituto Nacional de Pediatría, Secretaría de Salud, Mexico City 04530, Mexico., Flores-López LA; Laboratorio de Biomoléculas y Salud Infantil, CONAHCYT-Instituto Nacional de Pediatría, Mexico City 04530, Mexico., Martínez-Pérez Y; Instituto Tecnológico y de Estudios Superiores de Monterrey, Mexico City 14380, Mexico., López-Velázquez G; Laboratorio de Biomoléculas y Salud Infantil, Instituto Nacional de Pediatría, Secretaría de Salud, Mexico City 04530, Mexico. |
| المصدر: | Molecules (Basel, Switzerland) [Molecules] 2023 Aug 21; Vol. 28 (16). Date of Electronic Publication: 2023 Aug 21. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: MDPI Country of Publication: Switzerland NLM ID: 100964009 Publication Model: Electronic Cited Medium: Internet ISSN: 1420-3049 (Electronic) Linking ISSN: 14203049 NLM ISO Abbreviation: Molecules Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Basel, Switzerland : MDPI, c1995- |
| مواضيع طبية MeSH: | Triose-Phosphate Isomerase*/genetics , Neoplasms*/drug therapy, Humans ; Protein Processing, Post-Translational ; Cell Cycle ; Cell Proliferation |
| مستخلص: | Cancer involves a series of diseases where cellular growth is not controlled. Cancer is a leading cause of death worldwide, and the burden of cancer incidence and mortality is rapidly growing, mainly in developing countries. Many drugs are currently used, from chemotherapeutic agents to immunotherapy, among others, along with organ transplantation. Treatments can cause severe side effects, including remission and progression of the disease with serious consequences. Increased glycolytic activity is characteristic of cancer cells. Triosephosphate isomerase is essential for net ATP production in the glycolytic pathway. Notably, some post-translational events have been described that occur in human triosephosphate isomerase in which functional and structural alterations are provoked. This is considered a window of opportunity, given the differences that may exist between cancer cells and their counterpart in normal cells concerning the glycolytic enzymes. Here, we provide elements that bring out the potential of triosephosphate isomerase, under post-translational modifications, to be considered an efficacious target for treating cancer. |
| References: | Surg Today. 2006;36(12):1085-93. (PMID: 17123137) Biomolecules. 2020 Jul 15;10(7):. (PMID: 32679775) Cancer Res. 2017 Feb 15;77(4):817-822. (PMID: 28159861) Oncotarget. 2017 May 17;8(47):81953-81966. (PMID: 29137236) Biochem Biophys Res Commun. 2017 Jan 22;482(4):1048-1053. (PMID: 27908734) Brain. 2009 May;132(Pt 5):1335-45. (PMID: 19251756) Sci Rep. 2017 Sep 15;7(1):11722. (PMID: 28916747) Clin Chem. 2019 Aug;65(8):972-985. (PMID: 30872376) PLoS One. 2015 Apr 17;10(4):e0123379. (PMID: 25884638) Mol Cell Proteomics. 2018 Oct;17(10):2034-2050. (PMID: 30006487) Clin Orthop Relat Res. 2010 Nov;468(11):2833-9. (PMID: 20809165) Biochem Genet. 1985 Apr;23(3-4):267-80. (PMID: 4015618) Front Oncol. 2020 Mar 31;10:409. (PMID: 32300553) Sci Rep. 2023 May 5;13(1):7339. (PMID: 37147361) Mol Cell Proteomics. 2005 Nov;4(11):1686-96. (PMID: 16048908) Onco Targets Ther. 2017 Aug 07;10:3949-3956. (PMID: 28860802) J Cell Biochem. 2008 Aug 1;104(5):1625-35. (PMID: 18320592) Cell. 2011 Mar 4;144(5):646-74. (PMID: 21376230) ACS Med Chem Lett. 2015 Dec 28;7(3):217-22. (PMID: 26985301) Ecotoxicol Environ Saf. 2022 Aug;241:113757. (PMID: 35714482) Chin Med J (Engl). 2011 Nov;124(22):3806-9. (PMID: 22340245) Nat Biotechnol. 2020 Mar;38(3):365-373. (PMID: 31819260) Sci Rep. 2018 Jun 5;8(1):8591. (PMID: 29872223) Sci Rep. 2022 Mar 7;12(1):4028. (PMID: 35256749) Oncol Rep. 2011 Jul;26(1):185-91. (PMID: 21503584) Sci Signal. 2016 Aug 30;9(443):rs9. (PMID: 27577262) Cancer Discov. 2023 Apr 3;13(4):1002-1025. (PMID: 36715544) J Nucl Med. 1992 Dec;33(12):2154-60. (PMID: 1460508) Exp Mol Med. 2008 Dec 31;40(6):709-20. (PMID: 19116456) Cancer Discov. 2015 Oct;5(10):1024-39. (PMID: 26382145) J Proteome Res. 2009 Nov;8(11):4954-65. (PMID: 19764811) PLoS One. 2017 May 11;12(5):e0177489. (PMID: 28493957) Nat Rev Drug Discov. 2022 Feb;21(2):141-162. (PMID: 34862480) Biochim Biophys Acta. 2003 Oct 15;1639(2):121-32. (PMID: 14559119) Clin Cancer Res. 2006 Oct 1;12(19):5746-54. (PMID: 17020980) Proteomics. 2010 Jan;10(2):194-202. (PMID: 19899082) CA Cancer J Clin. 2021 May;71(3):209-249. (PMID: 33538338) J Alzheimers Dis. 2014;41(1):273-88. (PMID: 24614897) J Proteome Res. 2007 Feb;6(2):751-8. (PMID: 17269731) ACS Chem Biol. 2022 Oct 21;17(10):2769-2780. (PMID: 35951581) Cancer Res. 1976 Nov;36(11 Pt. 2):4291-4. (PMID: 61806) Cell Death Dis. 2019 Dec 4;10(12):914. (PMID: 31801946) Biosystems. 2023 Sep;231:104986. (PMID: 37506818) Mol Med Rep. 2020 Nov;22(5):3922-3934. (PMID: 33000180) Science. 2009 Aug 14;325(5942):834-40. (PMID: 19608861) Mol Cancer. 2013 Dec 03;12:152. (PMID: 24298908) Front Neurosci. 2015 Feb 09;9:23. (PMID: 25709564) Biochim Biophys Acta. 2009 Dec;1792(12):1168-74. (PMID: 19786097) Nat Metab. 2021 Jun;3(6):859-875. (PMID: 34140692) Mass Spectrom Rev. 2017 Nov;36(6):677-692. (PMID: 26763661) Cell Cycle. 2010 Dec 15;9(24):4931-40. (PMID: 21150329) Science. 2009 May 22;324(5930):1029-33. (PMID: 19460998) Clin Cancer Res. 2002 Jul;8(7):2298-305. (PMID: 12114434) Oncol Lett. 2021 May;21(5):410. (PMID: 33841571) Nucleic Acids Res. 2017 Jan 4;45(D1):D158-D169. (PMID: 27899622) Expert Opin Investig Drugs. 2008 Oct;17(10):1533-45. (PMID: 18808312) Chem Res Toxicol. 2019 Apr 15;32(4):668-680. (PMID: 30848893) Arch Biochem Biophys. 1992 Mar;293(2):382-90. (PMID: 1536574) Anal Cell Pathol. 2000;21(1):1-9. (PMID: 11254220) Proteomes. 2022 Jul 20;10(3):. (PMID: 35893766) Physiol Rev. 2020 Jan 1;100(1):407-461. (PMID: 31539311) Biochim Biophys Acta Gen Subj. 2017 Jan;1861(1 Pt A):3221-3236. (PMID: 27538376) Genet Mol Res. 2016 Apr 04;15(2):. (PMID: 27173185) Mol Cell Proteomics. 2014 Jan;13(1):240-51. (PMID: 24190977) Biochim Biophys Acta. 2003 Mar 21;1646(1-2):21-31. (PMID: 12637008) Cancer Med. 2023 Jul;12(14):15632-15649. (PMID: 37326348) Int J Med Chem. 2014;2014:469125. (PMID: 25383217) Mol Cell. 2013 Jun 27;50(6):919-30. (PMID: 23806337) Int J Mol Sci. 2013 Jul 16;14(7):14771-84. (PMID: 23863689) Fetal Pediatr Pathol. 2014 Aug;33(4):234-8. (PMID: 24840153) Cancer Lett. 2009 Aug 18;281(1):71-81. (PMID: 19299076) J Cancer. 2017 Aug 3;8(13):2575-2586. (PMID: 28900495) Anal Chem. 2016 Nov 1;88(21):10573-10582. (PMID: 27689507) Cell. 2010 Dec 23;143(7):1174-89. (PMID: 21183079) Oncol Rep. 2007 Apr;17(4):841-5. (PMID: 17342325) Nitric Oxide. 2018 Jul 1;77:26-34. (PMID: 29678765) Sci Rep. 2019 Mar 25;9(1):5047. (PMID: 30911085) Nat Struct Mol Biol. 2018 Jul;25(7):631-640. (PMID: 29967540) J Proteomics. 2014 Jan 16;96:253-62. (PMID: 24275569) J Enzyme Inhib Med Chem. 2023 Dec;38(1):2231169. (PMID: 37401012) Proc Natl Acad Sci U S A. 2001 Jan 30;98(3):944-9. (PMID: 11158575) Oncotarget. 2016 Jul 5;7(27):42740-42761. (PMID: 27057637) Sci Rep. 2019 Jun 20;9(1):8922. (PMID: 31222100) Genomics. 2004 Dec;84(6):1014-20. (PMID: 15533718) Proteomics. 2004 Aug;4(8):2465-75. (PMID: 15274141) Med Oncol. 2023 Apr 20;40(5):154. (PMID: 37079118) Jpn Dent Sci Rev. 2018 Feb;54(1):8-21. (PMID: 29628997) Cell Rep. 2013 Aug 29;4(4):842-51. (PMID: 23954790) J Physiol. 2021 Mar;599(6):1745-1757. (PMID: 33347611) Electrophoresis. 2009 Jun;30(12):2168-81. (PMID: 19582718) Cell. 2006 Nov 3;127(3):635-48. (PMID: 17081983) Cancer Med. 2018 Dec;7(12):6124-6136. (PMID: 30403008) Nat Commun. 2015 Mar 27;6:6622. (PMID: 25814448) Molecules. 2020 Apr 17;25(8):. (PMID: 32316657) Toxicol Res. 2016 Jul;32(3):177-93. (PMID: 27437085) Nature. 2017 Jan 5;541(7635):41-45. (PMID: 27974793) Cytometry A. 2020 Jan;97(1):15-23. (PMID: 31273910) Chem Biodivers. 2020 May;17(5):e2000012. (PMID: 32180338) Oncogene. 2006 Aug 7;25(34):4633-46. (PMID: 16892078) Front Endocrinol (Lausanne). 2021 Oct 12;12:753606. (PMID: 34712204) Cell Mol Life Sci. 2001 Sep;58(10):1451-60. (PMID: 11693526) Exp Gerontol. 2008 May;43(5):415-22. (PMID: 18166286) Vet Q. 2016 Jun;36(2):63-70. (PMID: 27018241) Drug Discov Today. 2005 Jul 15;10(14):965-76. (PMID: 16023055) Adv Clin Chem. 2021;101:121-133. (PMID: 33706887) Cell Rep. 2021 Dec 21;37(12):110137. (PMID: 34936872) Asian Pac J Cancer Prev. 2011;12(12):3479-82. (PMID: 22471501) Mol Diagn Ther. 2022 Jan;26(1):61-87. (PMID: 34773243) Int J Oncol. 2007 Apr;30(4):849-55. (PMID: 17332923) Invest Ophthalmol Vis Sci. 2012 Jul 09;53(8):4634-43. (PMID: 22570344) Redox Biol. 2021 Feb;39:101838. (PMID: 33360689) Int J Cancer. 2008 Jun 15;122(12):2726-34. (PMID: 18351643) Appl Microbiol Biotechnol. 2022 Jan;106(1):261-271. (PMID: 34910240) Cell. 2015 Jul 30;162(3):552-63. (PMID: 26232225) Oncogene. 2020 Sep;39(39):6139-6156. (PMID: 32839493) Aging (Albany NY). 2023 May 30;15(10):4533-4559. (PMID: 37253634) Ageing Res Rev. 2008 Jan;7(1):1-7. (PMID: 18162444) Bioorg Chem. 2020 Sep;102:104048. (PMID: 32682158) Int J Radiat Biol. 2019 Jul;95(7):912-919. (PMID: 30822194) Bioorg Chem. 2020 Mar;96:103609. (PMID: 32007722) Cancer Res Treat. 2003 Feb;35(1):9-15. (PMID: 26680909) ACS Nano. 2023 Aug 8;17(15):14667-14677. (PMID: 37486249) Proc Natl Acad Sci U S A. 2002 Mar 19;99(6):3505-10. (PMID: 11904414) Toxicology. 2010 Dec 5;278(2):224-8. (PMID: 20149834) J Exp Clin Cancer Res. 2023 Mar 31;42(1):78. (PMID: 36998085) |
| معلومات مُعتمدة: | CF-2023-1-811 Consejo Nacional de Ciencia y Tecnología |
| فهرسة مساهمة: | Keywords: S-nitrosylation; deamidation; glycolysis; phosphorylation; post-translational modification |
| المشرفين على المادة: | EC 5.3.1.1 (Triose-Phosphate Isomerase) |
| تواريخ الأحداث: | Date Created: 20230826 Date Completed: 20230828 Latest Revision: 20230829 |
| رمز التحديث: | 20240628 |
| مُعرف محوري في PubMed: | PMC10459230 |
| DOI: | 10.3390/molecules28166163 |
| PMID: | 37630415 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1420-3049 |
|---|---|
| DOI: | 10.3390/molecules28166163 |